Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study of telomerase reactivation with danazol on ovarian function
2018-004400-19Phase 3Terminated
- Sponsor
- IVI RMA Global
- Start
- Apr 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of danazol in Diminished Ovarian Reserve (DOR) and ovarian hypofunction (POI), sponsored by IVI RMA Global. Primary endpoint: Reduction in dysfunctional telomeres in granulosa cells. Started Apr 2019; status: terminated.
02
Drugs
danazol
03
Conditions
Diminished Ovarian Reserve (DOR)ovarian hypofunction (POI)
Beyond the preview
Go deeper on 2018-004400-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004400-19.